Evidence map›Paper›PMID 35783325›Full record

ArticleFrontiers in pediatrics2022

Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics.

Mikhail M Kostik, Ekaterina V Gaidar, Lubov S Sorokina, Ilya S Avrusin, Tatiana N Nikitina, Eugenia A Isupova, Irina A Chikova, Yuri Yu Korin, Elizaveta D Orlova, Ludmila S Snegireva and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mikhail M KostikSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Ekaterina V GaidarSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Lubov S SorokinaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Ilya S AvrusinSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Tatiana N NikitinaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Eugenia A IsupovaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Irina A ChikovaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Yuri Yu KorinSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Elizaveta D OrlovaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Ludmila S SnegirevaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Vera V MasalovaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Margarita F DubkoSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Olga V KalashnikovaSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
Vyacheslav G ChasnykSaint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Uveitis is the most frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA). Our study is aimed to evaluate the possible difference in arthritis course depending on uveitis presence in patients with JIA, treated with biologics. Methods: From our database of patients with JIA treated with biologics, we extracted patients to whom the first agent was administrated with or without MTX. The exclusion criteria included treatment with current systemic corticosteroids, infliximab, rituximab, observation period <3 years, and no missing data. After selection, 175 patients were eligible for analysis. We evaluated clinically significant flare with joint involvement (which required change of biologic or non-biologic DMARD) and time to flare. We compared two groups: (i) patients with uveitis ( Results: There was no difference in gender distribution and achievement of arthritis remission between groups. Patients in the non-uveitis group predominantly received etanercept (64.3%). In the uveitis group, the most prescribed biologic agent was adalimumab (71.9%). The presence of uveitis increased the risk of JIA flare, OR = 3.8 (95% CI: 1.7; 8.7), and the cumulative probability of joint flare, RR = 4.5 (95% CI: 1.7; 12.1), Conclusion: The presence of uveitis proved to be a risk factor in JIA flare. Methotrexate can decrease the cumulative flare probability. Further trials are required.

Indexed as

adalimumabflarejuvenile idiopathic arthritismethotrexateuveitis

Identifiers

PMID35783325
PMCPMC9240648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.